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ABSTRACT
Cancer immunotherapy based on the use of antibodies 
targeting the so- called checkpoint inhibitors, such 
as programmed cell death-1 receptor, its ligand, 
or CTLA-4, has shown durable clinical benefit and 
survival improvement in melanoma and other tumors. 
However, there are some special situations that could 
be a challenge for clinical management. Persons with 
chronic infections, such as HIV-1 or viral hepatitis, latent 
tuberculosis, or a history of solid organ transplantation, 
could be candidates for cancer immunotherapy, but their 
management requires a multidisciplinary approach. The 
Spanish Melanoma Group (GEM) panel in collaboration 
with experts in virology and immunology from different 
centers in Spain reviewed the literature and developed 
evidence- based guidelines for cancer immunotherapy 
management in patients with chronic infections and 
immunosuppression. These are the first clinical guidelines 
for cancer immunotherapy treatment in special challenging 
populations. Cancer immunotherapy in chronically infected 
or immunosuppressed patients is feasible but needs a 
multidisciplinary approach in order to decrease the risk of 
complications related to the coexistent comorbidities.
INTRODUCTION
Therapy with immune checkpoint inhibitors 
that block inhibitory receptors of effector 
lymphocytes mainly programmed cell 
death-1 (PD-1) and Cytotoxic T- Lymphocyte 
Antigen 4 (CTLA-4) or their ligand interac-
tions (PD- L1) is now the standard treatment 
for different types of cancers. However, data 
on the feasibility of using these therapies in 
patients with special clinical situations, such 
as chronic infections or immunosuppression, 
are scarce. HIV-1 infection, viral hepatitis, 
and previous solid organ transplantation are 
common exclusion criteria in most cancer 
clinical trials due to concerns about poten-
tial complications and the arguable balance 
between expected benefits and risks. Due 
to the relevant clinical benefit of immune 
checkpoint blockers in different types of 
cancer, including melanoma, development 
of evidence- based guidelines for the manage-
ment of these patients is relevant. These 
guidelines are not exclusively focused on 
melanoma treatment.
METHODS
A multidisciplinary panel of experts in 
medical oncology, dermatology, immunology 
and infectious diseases developed these 
clinical practice guidelines for the manage-
ment of approved cancer immunotherapy 
drugs (anti- PD-1/PD- L1 and anti- CTLA-4 
antibodies) in ‘special clinical situations’ 
related to HIV-1 infection, viral hepatitis, 
tuberculosis (TB) infection and solid organ 
transplantation. The authors developed the 
guidelines based on a critical review of liter-
ature, including case series, case reports and 
clinical trials, as well as their own observa-
tional data (online supplemental table S1). 
These guidelines are not intended to be a 
systematic review of the literature, but rather 
to develop a recommendation based on 
judgment of experts. Panelists discussed the 
final recommendations in a multidisciplinary 
cancer conference that was held in Barcelona 
on January 24, 2020 (https://www. groupgem. 
es/ eventos- 2020/). Due to the limitations of 
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the available evidence, the guidelines are non- mandatory 
recommendations. Levels of evidence and grade of recom-
mendation were classified according to the European 
Society for Medical Oncology guidelines (https://www. 
esmo. org/ Guidelines/ ESMO- Guidelines- Methodology).
HIV-1 INFECTION
Incidence and pathophysiology
Since the onset of the HIV/AIDS pandemic in 1981, 74.9 
million people have contracted HIV. AIDS- related illnesses 
account for 32 million deaths. In 2018, 37.9 million people 
were living with HIV (PLHIV) globally, 1.7 million people 
became newly infected, and 770,000 people died from 
AIDS- related illnesses (Joint United Nations Programme 
on HIV and AIDS Fact Sheet 2019). Life expectancy of 
PLHIV under viral suppressive combination antiretroviral 
therapy (cART) approaches that of non- infected persons, 
but the state of chronic inflammation prompts them to 
a higher risk of cancer and other comorbidities.1 This is 
the reason why cancer is now one of the leading causes 
of death in HIV-1- infected persons.2 Patients infected 
with HIV-1 have been excluded from clinical trials that 
evaluate cancer immunotherapies,3 4 but recently two 
prospective trials have shown the safety and feasibility 
of these therapies in PLHIV (online supplemental table 
S1).5 6 Previously, retrospective series and case reports 
had suggested similar safety and activity of anti- PD-1/
PD- L1 antibodies in PLHIV, compared with uninfected 
individuals.7–9 Grade 3 adverse events ranged from 0% 
to 20%, and grade 4 adverse events appeared in less 
than 1%.5 6 Also, antitumoral activity of anti- PD-1/PD- L1 
antibodies in PLHIV was demonstrated, with a disease 
control rate of 17%–50%.5 6 In the prospective studies, 
all patients included had undetectable plasma viral load 
(pVL) under cART. Moreover, throughout the anti- PD-1/
PD- L1 treatment, pVL remained undetected and CD4+ 
and CD8+ T cell counts were stable. Regarding baseline 
CD4+ T cell counts, most PLHIV on cART recover CD4+ T 
cell counts, but some individuals with delayed initiation of 
cART or who have received previous immunosuppressive 
therapies, such as chemotherapy, never recovered normal 
CD4+ T cell levels. The clinical trials led by Uldrick et al6 
and Gonzalez- Cao et al5 included six patients and one 
patient, respectively, with baseline CD4+ T cells below 
200 cells per mm3, without suffering any complications 
due to immunotherapy. Interestingly, one subject with a 
previously treated metastatic non- small cell lung cancer 
included in the DURVAST trial with baseline CD4+ T cell 
counts of 164 cells per mm3 had a long- lasting complete 
response (32+ months).5 10 Case reports also support the 
safety of treating patients with CD4+ T cell counts lower 
than 100 cells per mm3.11
Management and monitoring
Screening of HIV-1 infection previous to administration 
of immunotherapy is not mandatory, except for patients 
with AIDS- defining cancers or persons of groups at 
higher risk of HIV-1 infection, such as sex workers, men 
who have sex with men, or intravenous drug users (level 
of evidence III, grade of recommendation A).
HIV-1- infected individuals with tumor types that are 
candidates for immunotherapy must be considered for 
cancer treatment (level of evidence III, grade of recom-
mendation A). Pretreatment pVL must be checked. 
Immunotherapy should be administered when pVL is 
undetectable (level of evidence III, grade of recommen-
dation A). Patients must continue on cART therapy (level 
of evidence III, grade of recommendation A). It is not 
necessary to modify their cART when they start anticancer 
treatment with PD-1/PD- L1 antibodies if there is an 
effective viral suppression (level of evidence III, grade of 
recommendation C). Blips, defined as transitory detect-
able HIV viral load below 400 copies/mL, are frequent 
and have no clinical significance, so it is not necessary to 
modify anti- PD-1/PD- L1 therapy when blips are detected 
during therapy (level of evidence III, grade of recom-
mendation A). In patients with recent HIV-1 diagnosis, 
cART should be started prior to treatment with immuno-
therapy. Anti- PD-1/PD- L1 treatment should be delayed 
until viral suppression is achieved (level of evidence IV, 
grade of recommendation C). Viral suppression is gener-
ally achieved in most patients after 4 weeks on cART. In 
cases where anticancer treatment is an emergency, a 
simultaneous initiation of immunotherapy with cART 
could be considered, evaluating risk and benefits of every 
case, although there is no evidence of the safety of this 
procedure (level of evidence V, grade of recommenda-
tion C). For starting anti- PD-1/PD- L1 therapy, pretreat-
ment CD4+ T cell counts should preferably be above 200 
cells per mm3 (level of evidence III, grade of recommen-
dation B). 3 Patients with a CD4+ T cell counts below 100 
cells per mm3 have not been included in clinical trials of 
anti- PD-1/ PD- L1 antibodies. Therefore, while low CD4+ 
T cell counts are not an absolute contraindication to 
immunotherapy, careful evaluation of the risk to benefit 
ratio in these cases should be assessed (level of evidence 
V, grade of recommendation C) (figure 1).
The preferred anti- PD-1 antibody under this condition 
would be pembrolizumab due to availability of concor-
dant prospective and retrospective data demonstrating 
its safety and activity6 (level of evidence III, grade of 
recommendation B). Other anti- PD-1 antibodies have 
been used in this context with good tolerance, such as 
nivolumab12 (level of evidence IV, grade of recommen-
dation C). The preferred anti- PD- L1 antibody would be 
durvalumab because its safety has been demonstrated 
in one clinical trial5 (level of evidence III, grade of 
recommendation B). There are no prospective data on 
the safety and activity of other checkpoint inhibitors or 
combinations in PLHIV, but case reports and series of 
patients treated with ipilimumab or the combination of 
ipilimumab plus nivolumab7 8 suggest their safety (level of 
evidence IV, grade of recommendation C). Other clinical 
trials are ongoing in order to check the safety of other 
checkpoint inhibitors in PLHIV, but the mechanisms of 
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action of these therapies do not preclude any significant 
difference in tolerance and activity among the studied 
antibodies in this population.
Plasma viremia and CD4+ and CD8+ T cell counts must 
be periodically monitored (every 2 or 3 months) during 
immunotherapy (level of evidence III, grade of recom-
mendation B). If pVL becomes detectable in several 
consecutive analyses, drug resistance genotypic testing 




Worldwide, an estimated 257 million and 71 million 
people are living with chronic hepatitis B (HBV) and 
hepatitis C (HCV) viral infection, respectively.13 It should 
be kept in mind that the rate of chronic hepatitis B (hepa-
titis B surface antigen (HBsAg)- positive) is relatively low 
in most high- income countries (0.5%–2%); however, the 
percentage of subjects with evidence of resolved HBV 
infection (HBsAg- negative with anti- HBc- positive) is 
15%–20%.14 Although both viruses share the same ways 
of transmission and can produce chronic infection, there 
are multiple differences between HCV and HBV patho-
physiology. First, HBV, but not HCV, integrates into the 
human DNA, so when an immunosuppressed person 
gets infected, HBV could be reactivated, even in cases 
with an apparently resolved infection (HBsAg- negative 
with anti- HBc- positive). Second, the clinical evolution 
and dynamics of the viral infection are clearly different, 
suggesting that immune response dynamics are much 
more complex in HBV infection than in the case of HCV. 
While HCV infection evolution is predictable, in the case 
of HBV the clinical evolution is heterogeneous between 
patients. After HCV infection, some patients develop 
chronic viremia, and others have a completely resolved 
infection into the first 6 months after exposure.15 After 
this phase, most chronic HCV- infected patients slowly 
progress to severe liver disease after more than 20 years, 
with few exceptions.15 In comparison, HBV infection 
evolves in a much more heterogeneous and unpredict-
able way throughout its entire course. In chronic HBV 
infection, there are different stages with different levels of 
viral replication, immune response and liver function.15 
Finally, the third important difference between these two 
viruses is that HCV infection is curable with highly effec-
tive oral direct- acting antiviral agents (DAA),16 but there 
is no curative therapy for HBV (online supplemental data 
1 and table S2).
Treatment with immune checkpoint inhibitors in 
patients with chronic hepatitis deserves special consider-
ation as it could produce complications due to an impair-
ment in hepatic function in the case of an advanced 
liver disease, but also due to a reactivation of chronic 
infections. Feasibility of treatment with anti- PD-1/PD- L1 
antibodies in patients with cirrhosis was assessed in clin-
ical trials studying the efficacy of anti- PD-1 for patients 
with hepatocellular carcinoma (HCC). Most patients 
with HCC included in phase I/II studies of nivolumab,17 
pembrolizumab18 or durvalumab19 had compensated 
cirrhosis without unexpected drug- related adverse events. 
Few patients with decompensated cirrhosis have been 
treated with immunotherapy, but data suggest that treat-
ment is also well tolerated.20 From an overall perspective, 
monoclonal antibodies could be considered safe enough 
even in moderate hepatic insufficiency as liver metabo-
lism is not necessary for clearance.
Concerning the risk of viral reactivation, recent studies 
have demonstrated a high rate of viral reactivation of HBV 
when these patients are treated with anti- PD-1 antibodies 
(online supplemental table S1). The most important 
study included 114 HBsAg- positive patients treated with 
Figure 1 Diagram of management of HIV-1- infected patient candidates for immunotherapy. ART, antiretroviral therapy; cART, 
combination antiretroviral therapy; pVL, plasma viral load.
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an anti- PD-1 antibody for a median time of 18 weeks, 
showing a reactivation rate of 17%. When patients were 
simultaneously under treatment with antiviral therapy, 
the viral reactivation rate decreased to 1.2%.21 Other 
studies have also demonstrated in viral suppressed 
HBeAg- negative patients that checkpoint blockade is 
well tolerated without adverse events, and even immu-
notherapy was suggested to have some antiviral activity 
since HBsAg levels declined in most patients.22 A recent 
publication has also found that treatment with anti- PD-1 
antibodies with simultaneous treatment with antiviral 
drugs is safe and precludes viral reactivation.23 Indeed, 
general guidelines for immunosuppressed patients 
recommend antiviral prophylaxis for patients with occult 
HBV infection (HBsAg- negative, anti- HBc- positive, with 
detectable HBV DNA),24 although the risk of reactivation 
is very low,25 26 and that periodic monitoring of alanine 
aminotransferase levels, HBsAg and HBV DNA should be 
performed, with antiviral therapy deferred until confir-
mation of viral reactivation (seroconversion to HBsAg- 
positive or detectable HBV DNA). The most frequent 
antiviral drugs used for HBV are nucleoside or nucleotide 
analogs (NUCs), such as entecavir, tenofovir disoproxil or 
tenofovir alafenamide. Another consideration to be aware 
of is the case of development of immune- related adverse 
events during cancer immunotherapy. Patients treated 
with high- dose corticosteroids have a moderate risk of 
HBV reactivation, especially for cases on therapy for more 
than 4 weeks or when corticosteroids are combined with 
antitumor necrosis factor (anti- TNF) agents.24
In cases of HCV infection, anti- PD-1/PD- L1 and anti- 
CTLA-4 antibodies are also safe (online supplemental 
table S1). There is no viral reactivation, and moreover in 
some cases there is a decline in viral replication. A clin-
ical trial of tremelimumab, an anti- CTLA-4 antibody, in a 
cohort of 20 patients with HCC revealed a drop in HCV 
RNA in 75% of subjects. More recently, the anti- PD-1 anti-
body nivolumab demonstrated infection transient reduc-
tions in HCV RNA in 60 patients with HCC with HCV 
infection, although none achieved sustained virological 
suppression.17
In case of HCV infection, treatment with DAA should 
be based on the risk of progression of liver disease to 
HCC, according to the grade of liver fibrosis or cirrhosis, 
and the potential drug interactions.
Management and monitoring
All patients should be screened for hepatitis viral infec-
tion before starting immunotherapy (level of evidence 
III, grade of recommendation B).
Diagnosis of HCV infection is based on the presence of 
anti- HCV antibodies and HCV RNA in cases tested posi-
tive for anti- HCV. In patients who are HCV RNA- positive, 
it is mandatory to assess the severity of the liver disease 
using non- invasive markers in order to rule out advanced 
liver fibrosis or cirrhosis. In case of liver cirrhosis, liver 
ultrasound is recommended to exclude HCC, as well 
as gastroscopy in case of signs of portal hypertension 
(figure 2).
Screening of HBV infection is based on the performance 
of both HBsAg and anti- HBc. In patients with a resolved 
HBV infection, there is a potential risk of viral reactiva-
tion,24 especially in rare cases that have an ‘occult HBV 
infection’ (anti- HBc- positive with detectable HBV DNA). 
Figure 2 Diagram of clinical management of viral hepatitis- infected patient candidates for immunotherapy. ALT, alanine 
aminotransferase blood levels; DAA, direct- acting antiviral agents; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; 
HCV, hepatitis C virus; NUCs, nucleoside or nucleotide analogs; PD-1, programmed cell death-1; PD- L1, programmed cell 
death-1 ligand.
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Patients with HBV infection with positive HBsAg or were 
HBsAg- negative, and anti- HBc- positive with detectable 
HBV DNA, should be treated with NUCs before starting 
cancer immunotherapy (level of evidence III, grade of 
recommendation A). In case of patients with negative 
HBsAg and undetectable HBV DNA in plasma, but posi-
tive anti- HBc, a close monitoring of alanine aminotrans-
ferase blood levels (ALT) levels, HBsAg and HBV DNA 
should be performed every 6 months during cancer 
immunotherapy (level of evidence III, grade of recom-
mendation B). In case of ALT increment during immuno-
therapy, the first step should be urgent determination of 
both HBsAg and HBV DNA. When both are negative, the 
recommendation will be the same as that recommended 
for anti- HBc- negative subjects, although NUC prophy-
lactic therapy should be discussed in the case of immune- 
related adverse events development and a high dose of 
immune- suppressive drugs is needed (figure 2).
In patients following immunotherapy tretment who 
have no evidence of previous exposure to HBV and are 
unvaccinated (HBsAg negative/anti- HBc- negative/anti- 
HBs- negative), there are no available data on the effec-
tiveness or safety of HBV vaccination, so there is not 
enough evidence for or against vaccination recommen-
dation. The panel recommends no prophylactic HBV 
vaccination immunotherapy in persons without high risk 
of infection.
In patients with HCV diagnosis, DAAs are indicated, 
delaying anti- PD-1/PD- L1 treatment until viral suppres-
sion is achieved (level of evidence III, grade of recom-
mendation B). In cases where anticancer treatment must 
be started urgently, a simultaneous initiation of treatment 
with DAA could be considered (level of evidence V, grade 
of recommendation C) (figure 2).
TB INFECTION
Incidence and pathophysiology
TB is a global health challenge, now the second leading 
infectious cause of death in the world. Globally, in 2018, 
the incidence was 10 million people, and approximately 
9% are persons living with HIV infection. There were 
an estimated 1.2 million TB deaths among HIV- negative 
people and an additional 251,000 deaths among HIV-1- 
infected persons. In Europe, the estimated percentage 
of people infected by TB is around 3%27 (online supple-
mental data 2). Preventive therapy with isoniazid for 
latent TB was introduced 20 years ago. Older studies 
precluded a fatality rate due to severe hepatotoxicity in 
1%–19% of patients, but more recent studies, limiting the 
chemoprophylaxis to persons under 35 years old, have 
demonstrated a rate of clinical hepatotoxicity of only 1 
case per 1000 persons.28
In patients with cancer, TB could be difficult to identify 
since the most frequent symptoms (cough, night sweats, 
fever and weight loss) and interstitial infiltrates in the 
lung are similar to those produced by cancer.29
Recent data have suggested that treatment with check-
point inhibitors could reactivate latent TB, although few 
cases of TB reactivation by anti- PD-1/PD- L1 antibodies 
have been reported and the real incidence of reactiva-
tions during immunotherapy is unknown (online supple-
mental table S1).29–31 On the other hand, other therapies 
that are commonly used for toxicity management of 
checkpoint inhibitors, such as anti- TNF antibodies, have 
a higher risk of TB reactivation.29 32 33
Assessment and diagnosis
Mantoux tuberculin skin test (TST) or interferon gamma 
release assay (IGRA) is recommended before to immune 
checkpoint blockade administration (level of evidence 
V, grade of recommendation C).34 TST is the standard 
method for determining whether a person is infected 
with Mycobacterium tuberculosis (MT). However, TST has 
sensitivity problems, with poor or non- existent response 
in patients with impaired cellular immunity, and also low 
specificity, given that some antigens are shared by non- 
tuberculosis mycobacteria (NTM) and BCG vaccines 
previously inoculated. IGRA is a blood test that works by 
measuring the immune response to the TB bacteria. An 
IGRA test is not reactive to BCG vaccine or most NTM, so 
IGRA is more sensitive than TST in immunosuppressed 
individuals, more specific in the BCG vaccinated popu-
lation, and in people infected with NTM. For patients 
with cancer, IGRA is preferred over TST. Both techniques 
demonstrate an immune response to MT antigens, rather 
than a true infection by the micro- organism. All positive 
patients must be evaluated to rule out active TB (level of 
evidence IV, grade of recommendation A). The evalua-
tion includes clinical history, physical examination, and 
chest X- radiograph (or thoracic CT scan) and respiratory 
sampling. Patients with relevant clinical manifestations 
and/or abnormal chest X- radiograph should submit 
three sputum specimens (obtained via cough or induc-
tion at least 8 hours apart and including at least one early 
morning specimen) for acid- fast bacilli smear, mycobac-
terial culture, and nucleic acid amplification testing. Of 
these tests, the more sensitive are the molecular tech-
niques that analyze the nucleic acid amplification, such as 
Xpert MTB/RIF or first- line and second- line Line probe 
assays (LPA). All unexpected suspicious lung lesions 
depicted by imaging should be investigated or biopsied, 
if possible.29 Importantly, in addition to TB reactivation, 
the differential diagnosis in such situations should always 
include metastatic progressive disease and granulomatous 
sarcoid- like reactions during cancer immunotherapy.
Management and monitoring
Patients with an IGRA positive test without diagnosis of 
active TB could be considered for TB chemoprophylaxis 
before starting immunotherapy (level of evidence V, 
grade of recommendation C). Data available regarding 
chemoprophylaxis in patients with cancer immuno-
therapy are scarce, and this therapeutic strategy is based 
on data from patients treated with anti- TNF-α antibodies. 
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Treatment during 4 weeks with isoniazid (plus rifapen-
tine) significantly reduces the risk of developing active 
TB.35 Most studies suggest that treatment with isoniazid 
(plus rifapentine) should be initiated at least 1 month 
before anti- TNF-α administration, although it could be 
initiated at any time, even concurrent with anti- TNF-α 
administration. When a serious immune- related adverse 
event occurs, delaying anti- TNF-α is not reasonable. The 
main concern about chemoprophylaxis in patients who 
must complete immunotherapy is that isoniazid is hepa-
totoxic and it can increase the risk of immune- related 
liver toxicity. Moreover, when anti- PD-1/PD- L1 therapy 
is used in the adjuvant setting, delaying therapy until 
completion of chemoprophylaxis could be reasonable. 
However, in the advanced setting, recommendation to 
delay cancer treatment must be taken with caution. The 
panel cannot make a formal recommendation about 
chemoprophylaxis during immunotherapy, and the risk 
of hepatotoxicity must be balanced considering the low 
frequency of TB reactivation reported in the literature. 
Chemoprophylaxis could be mainly considered for young 
patients before adjuvant treatment, but in patients with 
advanced tumors, mainly older persons, delaying immu-
notherapy or assuming a high risk of toxicity starting 
chemoprophylaxis in combination with immunotherapy 
is not justified (level of evidence V, grade of recommen-
dation C). Patients who have initiated chemoprophy-
laxis should be monitored for clinical signs of hepatitis 
during TB chemoprophylaxis (level of evidence II, grade 
of recommendation A). In patients with hepatotoxicity 
due to chemoprophylaxis, chemoprophylaxis should be 
permanently discontinued, while immunotherapy should 
be reinitiated when hepatotoxicity is resolved (figure 3).
In case of active TB or TB reactivation during immuno-
therapy, immunotherapy must be withheld due to the possi-
bility of an exaggerated inflammatory response (level of 
evidence IV, grade of recommendation A). Treatment should 
be started with high- dose corticosteroids and combination 
of isoniazid, rifampicin, pyrazinamide, and ethambutol for 
8 weeks, followed by isoniazid and rifampicin for 18 weeks 
(level of evidence II, grade of recommendation A) (figure 3). 
There is no evidence about the exact time for resumption 
of immunotherapy after initiation of anti- TB treatment or if 
the immunotherapy must be permanently stopped. Several 
factors should be considered, including the severity of TB 
infection, overall tumor burden, tumor control, and comor-
bidities. In case of adjuvant immunotherapy, completion 
of anti- TB therapy should be the preferred option (level of 
evidence IV, grade of recommendation B) (figure 3). In case 
of immunotherapy for advanced cancer, a short course of TB 
therapy of at least 2 weeks is recommended before restarting 
cancer immunotherapy (level of evidence V, grade of recom-
mendation C). In case of restarting immunotherapy, close 
monitoring is mandatory in order to check for overlapping 
toxicities, especially liver toxicities (level of evidence V, grade 
of recommendation C) (figure 3).
SOLID TRANSPLANT RECIPIENTS
Incidence and pathophysiology
Long- term survival after solid organ transplantation has 
increased during the last decades. Solid organ transplant 
recipients (SOTRs) require lifelong immunosuppression. 
The required level of immunosuppression varies between 
different organ transplant types, with liver transplant being 
the one needing the lowest level. Calcineurin inhibitors, 
ciclosporin and tacrolimus, blocking signal 2 of T cell acti-
vation are the main immunosuppressive medications used 
in combination with agents that interact with the cell cycle, 
such as mycophenolate mofetil. It is unclear whether these 
drugs interfere with the antitumor effect of anticancer immu-
notherapy, but SOTRs who develop malignant tumors pose 
Figure 3 Diagram of TB screening and treatment of patient candidates for immunotherapy. IGRA, interferon gamma release 
assay; IO, Immunotherapy; LTBI, latent tuberculosis; PD-1, programmed cell death-1; PD- L1, programmed cell death-1 ligand; 
PE, physical examination; TB, tuberculosis; TST, Mantoux tuberculin skin test.
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a challenge for anticancer immunotherapy because T cell 
stimulation is implicated as one of the major mediators of 
allograft rejection.
The incidence of de novo malignancies, including non- 
melanoma skin cancer, malignant melanoma, lymphoma, 
kidney, head and neck cancer, colorectal cancer, and lung 
cancer, is high in organ transplant recipients. These patients 
have been excluded from clinical trials with immune check-
point inhibitors and the benefit and risks of such treatment 
have not been systematically evaluated in SOTRs.36 Serious 
immune- related adverse events seem to be as common as in 
the general population, although they are more frequent 
in patients without graft rejection. The main concern in 
these patients is the risk of graft rejection that occurs in 
37%–41% of patients, with graft loss in almost 80% of cases 
and death due to graft rejection in 38%–45%.37–41 Published 
data demonstrated no association with the length of time 
after organ transplantation and the risk of organ rejection. 
Although the rates of rejection are similar according to 
the different organs transplanted, analysis of case reports 
including data from 57 cases suggested that the rates of death 
secondary to graft rejection were higher in liver transplant 
patients (30%) than kidney (6%) or heart transplant (0%) 
patients.38 Tumor response rate with anti- PD-1/PD- L1 or 
with anti- CTLA-4 antibodies varies between 25% and 40%, 
depending on cancer histology subtype (online supplemental 
table S1).37–41 According to immunosuppressant medica-
tion, patients receiving low doses of prednisone (≤10 mg/
day) seemed to have numerically higher tumor responses 
to immunotherapy with check point inhibitors therapy than 
those receiving mechanistic Target of Rapamycin (mTOR) 
inhibitors, calcineurin, or combination immunosuppressant 
therapy (63% compared with 42%), but in some series they 
also have a higher risk of graft rejection (78% vs 11%),37 
whereas this has not been confirmed by others.38 So it is clear 
that SOTRs have a high allograft rejection rate that happens 
soon after immunotherapy initiation, with a high mortality 
rate.37–41 Immunotherapy reinitiation can be considered in 
patients who survived after graft rejection, supported by some 
case reports of treatment reinitiation in patients dependent 
on hemodialysis.42–44 Close collaboration between specialists 
is required to ensure an optimal patient management. Once 
the treating physician has determined that immunotherapy is 
the best option, the patient should always be informed about 
the risks to allow a shared decision.
Management and monitoring
There is no absolute contraindication for SOTRs with 
cancer to be treated with immunotherapy. The physician 
should raise a thorough discussion about the expected 
benefits and risks with the patient. Especially, treatment of 
patients with renal allograft must be considered. Patients’ 
characteristics, the probability of achieving long- term 
survival, and alternative anticancer therapies should be 
considered (level of evidence V, grade of recommendation 
A).
When cancer immunotherapy is used in SOTRs, periodic 
examinations are required to closely monitor symptoms and 
serum levels of immunosuppressant drugs and to periodically 
adjust immunosuppressant drug doses or make drug modifi-
cations (level of evidence V, grade of recommendation C).
If graft rejection occurs, high- dose corticosteroids or other 
immunosuppressive therapies are used. In case of renal trans-
plant, dialysis is usually required (level of evidence V, grade of 
recommendation A). Cancer immunotherapy must be with-
held in these cases until full recovery (level of evidence V, 
grade of recommendation A). Immunotherapy reinitiation 
can be considered in patients who recover after graft rejec-
tion, especially in cases with renal transplant, who can survive 
in case of a graft loss (level of evidence V, grade of recom-
mendation C) (figure 4).
Figure 4 Diagram of immunotherapy management of patients with previous solid organ transplants. *Consider immunotherapy 
for patients with cancer histologies with high chances of responding to immunotherapy and in patients with good PS and no 
other comorbidities. PS, performance status; SOTRs, solid organ transplant recipients.
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OTHER CHALLENGING POPULATIONS: ALLOGENEIC 
TRANSPLANT, PREGNANCY AND AUTOIMMUNE DISORDERS
Incidence and pathophysiology
Other clinical challenging scenarios for treatment with 
checkpoint inhibitors include autoimmune disorders, cancer 
during pregnancy, and allogeneic transplant recipients 
(online supplemental table S1).
Treatment with anti- PD-1 antibodies yields a high rate of 
response in Hodgkin’s lymphoma, but most patients will also 
be candidates for hematopoietic cell transplantation. Allo-
geneic bone marrow transplantation in patients previously 
treated with anti- PD-1 antibodies has a high risk of compli-
cations, mainly due to graft- versus- host disease, yielding high 
rates of antitumoral responses due to a simultaneous graft 
versus lymphoma effect.45 Similarly, anti- PD-1 therapy after 
allogeneic bone marrow transplantation has a high risk of 
graft- versus- host disease and immune- related toxicities, but 
it could be considered for patients with no other treatment 
options options.45
Although cancer during pregnancy is uncommon, when 
it occurs, is not unusual that immunotherapy with anti- PD-1 
or anti- CTLA-4 antibodies is indicated, because the most 
frequent tumor during pregnancy is melanoma. In order 
for the fetus to not be rejected by the immune system of 
the mother, there is a state of immune tolerance during 
pregnancy. Theoretically, the inhibition of PD-1/PD- L1 or 
CTLA-4 during pregnancy will increase the risk of abortion 
and premature delivery, although three case reports in the 
literature have reported treatment with nivolumab, or in 
combination with ipilimumab, without relevant obstetric 
complications.46–48 These drugs probably do not increase the 
risk of malformations, but data on their teratogenic potential 
in humans are lacking.
Autoimmune disorders increase the risk of cancer devel-
opment, including melanoma, so they produce a stage of 
chronic inflammation. One would expect that patients 
with autoimmune diseases would have an increased risk of 
immune- related adverse events in case they are treated with 
anti- PD-1/PD- L1 or anti- CTLA-4 antibodies. Several retro-
spective series have presented data on the safety and activity of 
immunotherapy in patients with autoimmune disorders.49 50 
In summary, flare- ups of the pre- existing autoimmune disease 
were reported in 27%–50% of cases, including 10%–25% of 
high grade; moreover, 25%–30% of cases presented other 
immune- related adverse events, although a high response 
rate is suggested in this population.49 50
Management and monitoring
Previous treatment with allogeneic bone marrow transplan-
tation is not an absolute contraindication to treatment with 
anti- PD-1 antibodies, and the same is true for patients previ-
ously treated with anti- PD-1 antibodies that are candidates for 
allogeneic bone marrow transplantation (level of evidence V, 
grade of recommendation A).
Pregnancy during treatment with immunotherapy must 
be avoided (level of evidence V, grade of recommendation 
A). In pregnant patients, treatment with checkpoint inhib-
itors is not absolutely contraindicated, although the risk of 
pregnancy complications is increased (level of evidence V, 
grade of recommendation A).
In patients with a pre- existing autoimmunity, immu-
notherapy is not an absolute contraindication, but every 
case must be individually evaluated (level of evidence V, 
grade of recommendation A).
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